NICE Technology Appraisals: Formulary Adherence Checklist

NICE technology appraisals (TAs) are published on the fourth Wednesday of each month, except for December when it is published earlier

Produced by Medicines Information, Pharmacy, Sunderland Royal Hospital

Updated 8/11/17

Technology appraisal (TA) Titles are hyperlinks to full guidance		***Availability of medicine for NHS patients with this medical condition, as indicated by NICE***	***Adherence of local formulary to NICE***							
			Yes *(mark 'x' if applicable)*	***N/A*** *(mark 'x' if applicable)*	***Published***	***Date of local decision*** *(DD/MM/YY)*	***Final Date to Implement***	***Time to implement*** *as requested by NICE (days)*	***Time taken to implement in Sunderland*** *(days)*	***Notes***
2017-18										
TA486	Aflibercept for treating choroidal neovascularisation	Aflibercept is recommended, within its marketing authorisation, as an option for treating visual impairment because of myopic choroidal neovascularisation in adults	X		01/11/2017	29/11/2017	30/01/2018	90	28	Already listed in the Formulary
TA485	Sarilumab for moderate to severe rheumatoid arthritis	Sarilumab, with methotrexate, is recommended as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to intensive therapy with a combination of conventional disease-modifying antirheumatic drugs (DMARDs), only if disease is severe (a disease activity score [DAS28] of more than 5.1)	X		01/11/2017	29/11/2017	30/01/2018	90	28	
TA484	Nivolumab for previously treated non-squamous non-small-cell lung cancer	Nivolumab is recommended for use within the Cancer Drugs Fund as an option for treating locally advanced or metastatic non-squamous non-small-cell lung cancer in adults after chemotherapy, only if their tumours are PD-L1 positive and nivolumab is stopped at 2 years of uninterrupted treatment, or earlier in the event of disease progression	X		01/11/2017	29/11/2017	30/01/2018	90	28	Already listed in the Formulary; CDF
TA483	Nivolumab for previously treated squamous non-small-cell lung cancer	Nivolumab is recommended for use within the Cancer Drugs Fund as an option for treating locally advanced or metastatic squamous non-small-cell lung cancer in adults after chemotherapy, only if nivolumab is stopped at 2 years of uninterrupted treatment, or earlier in the event of disease progression	X		01/11/2017	29/11/2017	30/01/2018	90	28	Already listed in the Formulary; CDF

TA482	Immunosuppressive therapy for kidney transplant in children and young people	This guidance makes recommendations on using basiliximab, rabbit anti-human thymocyte immunoglobulin, tacrolimus (immediate-release and prolonged-release), mycophenolate mofetil, mycophenolate sodium, sirolimus, everolimus and belatacept after kidney transplant in children and young people. The recommendations apply only to the initial immunosuppressive therapy (induction and maintenance therapy) started around the time of kidney transplant.	X		11/10/2017	29/11/2017	09/01/2018	90	49	Tertiary
TA481	Immunosuppressive therapy for kidney transplant in adults	This guidance makes recommendations on using basiliximab, rabbit anti-human thymocyte immunoglobulin, tacrolimus (immediate-release and prolonged-release), mycophenolate mofetil, mycophenolate sodium, sirolimus, everolimus and belatacept after kidney transplant in adults. The recommendations apply only to the initial immunosuppressive therapy (induction and maintenance therapy) started around the time of kidney transplant	X		11/10/2017	29/11/2017	09/01/2018	90	49	Tertiary
TA480	Tofacitinib for moderate to severe rheumatoid arthritis	Tofacitinib, with methotrexate, is recommended as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to, or who cannot have, other DMARDs, including at least 1 biological DMARD, only if disease is severe (a DAS28 of more than 5.1) and they cannot have rituximab. Tofacitinib can be used as monotherapy for adults who cannot take methotrexate because it is contraindicated or because of intolerance, when the above criteria are met.	X		11/10/2017	29/11/2017	09/01/2018	90	49	
TA479	Reslizumab for treating severe eosinophilic asthma	Reslizumab, as an add-on therapy, is recommended as an option for the treatment of severe eosinophilic asthma that is inadequately controlled in adults despite maintenance therapy with high-dose inhaled corticosteroids plus another drug, only if the blood eosinophil count has been recorded as 400 cells per microlitre or more; the person has had 3 or more severe asthma exacerbations needing systemic corticosteroids in the past 12 months	X		04/10/2017	29/11/2017	02/01/2018	90	56	
TA478	Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma | Guidance and guidelines | NICE	Brentuximab vedotin is recommended as an option for treating relapsed or refractory systemic anaplastic large cell lymphoma in adults, only if they have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.	X		04/10/2017	29/11/2017	02/01/2018	90	56	NECN

TA477	Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee	Autologous chondrocyte implantation (ACI) is recommended as an option for treating symptomatic articular cartilage defects of the knee, only if NICE Criteria are met.		X	04/10/2017	29/11/2017	02/01/2018	90	56	Not a drug
10			9	1						
			% "Yes"	**% "N/A"**					**Average implement time** (days)	
	Adherence statistics for 2017-18		90%	10%					**43**	